Home Cart Sign in  
Chemical Structure| 116666-63-8 Chemical Structure| 116666-63-8

Structure of Mibefradil 2HCl
CAS No.: 116666-63-8

Chemical Structure| 116666-63-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Mibefradil 2HCl is calcium channel blocker with moderate selectivity for T-type Ca2+ channels displaying

Synonyms: Ro 40-5967 dihydrochloride; Mibefradil (dihydrochloride); Posicor

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Mibefradil 2HCl

CAS No. :116666-63-8
Formula : C29H40Cl2FN3O3
M.W : 568.55
SMILES Code : O=C(O[C@@]1(CCN(CCCC2=NC3=CC=CC=C3N2)C)[C@@H](C(C)C)C4=C(C=C(F)C=C4)CC1)COC.[H]Cl.[H]Cl
Synonyms :
Ro 40-5967 dihydrochloride; Mibefradil (dihydrochloride); Posicor
MDL No. :MFCD00881804
InChI Key :MTJLQTFHJIHXIX-GDUXWEAWSA-N
Pubchem ID :60662

Safety of Mibefradil 2HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HEK293 T-REx cells 52.6 μM (Orai1), 14.1 μM (Orai2), 3.8 μM (Orai3) 24-72 hours To investigate the inhibitory effect of Mibefradil on Orai channels. Results showed Mibefradil dose-dependently inhibited Orai1, Orai2, and Orai3 currents. Br J Pharmacol. 2019 Oct;176(19):3845-3856
Glioblastoma stem-like cells (GSC) 5 μM 24-48 hours Mibefradil significantly suppressed HIF1α and HIF2 expressions Cancer Res. 2017 Jul 1;77(13):3479-3490
Glioblastoma stem-like cells (GSC) 5 μM 48 hours Mibefradil significantly enhances cell death, with enhanced effects in combination with TMZ Cancer Res. 2017 Jul 1;77(13):3479-3490
Glioblastoma stem-like cells (GSC) 5 μM 5 days Mibefradil significantly inhibited cell proliferation and enhanced the inhibition of GSC proliferation by TMZ Cancer Res. 2017 Jul 1;77(13):3479-3490
Glioblastoma stem-like cells (GSC) 2.5-5 μM 48 hours Mibefradil significantly inhibited cell growth and enhanced the inhibition of GSC growth by TMZ Cancer Res. 2017 Jul 1;77(13):3479-3490
HT144 human melanoma cells 7 μM 24 hours To evaluate the effect of Mibefradil on apoptosis, results showed Mibefradil increased the percentage of apoptotic cells in adaptive cells Br J Cancer. 2020 Mar;122(7):1023-1036
SK-MEL-28 human melanoma cells 7 μM 24 hours To evaluate the effect of Mibefradil on apoptosis, results showed Mibefradil increased the percentage of apoptotic cells in adaptive cells Br J Cancer. 2020 Mar;122(7):1023-1036
A375 human melanoma cells 7 μM 24 hours To evaluate the effect of Mibefradil on apoptosis, results showed Mibefradil increased the percentage of apoptotic cells in adaptive cells Br J Cancer. 2020 Mar;122(7):1023-1036
4434 mouse melanoma cells 7 μM 24 hours To evaluate the effect of Mibefradil on apoptosis, results showed Mibefradil increased the percentage of apoptotic cells in partially reprogrammed cells Br J Cancer. 2020 Mar;122(7):1023-1036
C790 mouse melanoma cells 7 μM 24 hours To evaluate the effect of Mibefradil on apoptosis, results showed Mibefradil increased the percentage of apoptotic cells in partially reprogrammed cells Br J Cancer. 2020 Mar;122(7):1023-1036
Jurkat cells 2-10 μM 48 hours Mibefradil significantly inhibited the growth of Jurkat cells, mainly by inducing apoptosis. J Exp Clin Cancer Res. 2015 May 21;34(1):54
MOLT-4 cells 2-10 μM 48 hours Mibefradil inhibited the proliferation of MOLT-4 cells and induced apoptosis by blocking T-type Ca2+ channels and down-regulating ERK1/2 signaling pathway. J Exp Clin Cancer Res. 2015 May 21;34(1):54
HK-2 cells 1-25 μM 24 hours To study the effect of Mibefradil on cell cycle. Results showed low concentrations of Mibefradil increased the percentage of cells at G0/G1 phase, while high concentrations decreased the percentage of cells at S phase and G2/M phase. Br J Pharmacol. 2019 Oct;176(19):3845-3856
rat primary cortical neurons 10 μM As a low-voltage–activated (T-type) Ca2+ channel blocker for spatially resolved chemical neuromodulation, it did not effectively block Ca2+ signal propagation Sci Adv. 2023 Mar 10;9(10):eadf0925
rat afferent arteriole vascular smooth muscle cells 1 μM 10 minutes To investigate the effect of Mibefradil on Ca2+ entry induced by KCl-induced membrane depolarization. Results showed that Mibefradil did not significantly affect KCl-induced Ca2+ entry. Hypertension. 2015 Aug;66(2):374-81

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Immunodeficient mice GSC 827-derived glioblastoma murine xenografts Oral gavage 24 mg/kg Every 6 hours for 4 days, stopped for 7 days, total two cycles Mibefradil significantly inhibited tumor growth and prolonged host survival, with additive effects when combined with TMZ Cancer Res. 2017 Jul 1;77(13):3479-3490
NSG mice HT144 and A375 xenograft models Oral 0.25 mg/mL Once daily for 5 days To evaluate the effect of Mibefradil on tumor growth, results showed Mibefradil significantly reduced tumor volume and improved survival rate Br J Cancer. 2020 Mar;122(7):1023-1036

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02024919 Coronary Artery Ectasia Not Applicable Completed - Turkey ... More >> Ankara University School Of Medicine, Department of Cardiology Ankara, Turkey, 06230 Less <<
NCT01480050 Brain and Central Nervous Syst... More >>em Tumors Less << Phase 1 Completed - United States, Alabama ... More >> UAB Comprehensive Cancer Center Birmingham, Alabama, United States, 35294-3410 United States, Georgia Winship Cancer Institute of Emory University Atlanta, Georgia, United States, 30322 United States, Maryland Johns Hopkins University Baltimore, Maryland, United States, 21205 United States, Michigan Henry Ford Hospital Detroit, Michigan, United States, 48202 United States, North Carolina Wake Forest University Comprehensive Cancer Center Winston-Salem, North Carolina, United States, 27157-1096 United States, Pennsylvania Abramson Cancer Center of the University of Pennsylvania Philadelphia, Pennsylvania, United States, 19104-4283 Hillman Cancer Center at University of Pittsburgh Cancer Institute Pittsburgh, Pennsylvania, United States, 15232 Less <<
NCT02202993 Glioblastoma Multiforme (GBM) Phase 1 Completed - United States, Connecticut ... More >> Yale University New Haven, Connecticut, United States, 06520 Less <<
NCT01550458 Healthy Phase 1 Completed - United States, Nebraska ... More >> Celerion, Inc. Lincoln, Nebraska, United States, 68502 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.76mL

0.35mL

0.18mL

8.79mL

1.76mL

0.88mL

17.59mL

3.52mL

1.76mL

References

 

Historical Records

Categories